MINNEAPOLIS (August 22, 2017) – On Wednesday, August 23 and Thursday, August 24, OneOme’s director of laboratory operations, Ross Higgins, will speak about the barriers and opportunities for implementing pharmacogenomics in clinical medicine at the Precision Medicine Leaders Summit in San Diego. The event, which features influential precision medicine innovators from across the world, takes place at the Hilton San Diego Bayfront hotel.
OneOme’s RightMed® pharmacogenomic test uses the power of DNA to predict which medications may work best for an individual patient. Pharmacogenomics is an emerging field that combines the study of how drugs affect our bodies (pharmacology) with the study of our genes and their functions (genomics).
Pharmacogenomics can improve patient health by increasing drug effectiveness, as well as decreasing side effects, adverse drug reactions, and unintended interactions with other drugs. The RightMed solution better enables providers to more effectively treat conditions in primary care and a variety of specialty areas including mental health, cancer, heart disease, and more. The OneOme RightMed pharmacogenomic test covers 28 medical indications and 340+ drugs at an accessible price point.
At the Wednesday, August 23 roundtable Higgins will discuss the barriers and opportunities for implementing pharmacogenomics into routine clinical practice. On Thursday, August 24, Higgins joins a panel discussion that calls for routine pharmacogenomic testing in the clinic.
WHAT: OneOme participates in 2017 Precision Medicine Leaders Summit
WHERE: Hilton San Diego Bayfront 1 Park Blvd, San Diego
WHEN: Wednesday, August 23, 6:00-6:45 p.m. Thursday, August 24, 2:45-3:30 p.m.
WHO: Ross Higgins, MBA, OneOme Director of Laboratory Operations
Ross Higgins joined OneOme in early 2016 and is responsible for overseeing laboratory operations and clinical development at the company. Most recently, Higgins served in a dual business development and product management role for Douglas Scientific, where he was responsible for driving both product development and market expansion efforts. Higgins also brings extensive experience in the clinical laboratory field, having managed the molecular genetics department at a large, CAP-accredited reference laboratory. Higgins earned a B.S. in Clinical Laboratory Sciences and an M.B.A. from Virginia Commonwealth University. He also maintains ASCP certification as a Medical Laboratory Scientist.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more, visit oneome.com.
Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.